Chiang Mai University HIV/AIDS Clinical Trials Unit

清迈大学艾滋病毒/艾滋病临床试验单位

• 批准号: 8415777
• 负责人: THIRA SIRISANTHANA
• 金额: $ 156.16万
• 依托单位: CHIANG MAI UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-15 至 2013-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8415777
• 关键词: AIDS clinical trial group; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Adolescent; Asia; Blood donor; Centers for Disease Control and Prevention (U.S.); Child; China; Clinic; Clinical; Clinical Management; Clinical Trials Cooperative Group; Clinical Trials Unit; Communicable Diseases; Communities; Country; County; Couples; Discipline of obstetrics; Disease Marker; Drug user; Epidemic; Faculty; Foundations; Grant; HIV; HIV Infections; HIV Vaccine Trials Network; Health Sciences; Housing; India; Laboratories; Lead; Medicine; Military Personnel; Monitor; National Institute of Allergy and Infectious Disease; National Institute of Child Health and Human Development; National Institute of Drug Abuse; National Institute of Mental Health; Patients; Pediatrics; Pharmacy facility; Population; Pregnant Women; Prevention; Principal Investigator; Process; Public Health; Research; Research Infrastructure; Research Institute; Research Priority; Research Project Grants; Resources; Shipping; Ships; Site; Thailand; Translational Research; USAID; Universities; Vertical Disease Transmission; Vietnam; Walking; clinical research site; data management; epidemiology study; experience; male; sample collection; sex

DESCRIPTION (provided by applicant): Chiang Mai University (CMU), Thailand, is proposing to establish the CMU HIV/AIDS Clinical Trials Unit, Thira Sirisanthana, Principal Investigator. The CMU CTU consists of an administrative component located at the Research Institute for Health Sciences (RIHES), CMU, where the main resources for specimen collection, processing and shipping, clinical laboratory assessments, data management, pharmacy, regulatory compliance, fiscal management and administration are housed. Clinical facilities within walking distance are located at the Faculty of Medicine, CMU. This CTU will have 3 Clinical Research Sites (CRSs), the GMU AIDS Clinical Trials Group Clinical Research Site (CMU ACTG CRS), Khuanchai Supparatpinyo, site leader, affiliated with the newly formed Aids Clinical Trials Group (ACTG) network; the HIV Vaccine Trial Network Clinical Research Site (CMU HVTN CRS), Vinai Suriyanon, site leader, affiliated with the newly formed HIV Vaccine Trial Network (HVTN); and the Pediatrics-Obstetrics Clinical Research Site (CMU PEDOB CRS), Virat Sirisanthana, site leader, which will focus on research priorities in mother-to-child transmission of HIV, as well as optimization of clinical management and translational research in children, adolescents, and pregnant women. RIHES and its collaborators began research in HIV/AIDS in 1988 in studios mounted to monitor infectious disease markers among blood donors. In 1991 with a grant from the Rockefeller Foundation, RIHES studied the epidemiology of HIV infection in military conscripts and later expanded to include other populations, such as sex workers, STD clinic patients, IDUs, non-injecting drug users, factory workers, couples with an infected male partner, and community populations. Collaborative partnership have been formed with the Johns Hopkins University, the Royal Thai Army and the Ministry of Public Health. Research grant support has come from NIAID, NICHD, NIDA, NIMH, CDC/CONRAD, AIDSCAP/USAID, WRAIR, WHO, and the Rockefeller Foundation. Thailand was the first country in Asia with a major AIDS epidemic. The Thai epidemic curve leads those in India, China, and Vietnam by 5 - 10 years. With the countries of Asia having similar culture, Thailand has the infrastructure and the experience to lead them in the HIV/AIDS prevention and treatment research. Finally, Thailand is perhaps the only county in the world where the CRF_01 AE form of HIV can be optimally studied. ADMINISTRATIVE COMPONENT:

描述（由申请人提供）：泰国清迈大学 (CMU) 提议建立 CMU HIV/艾滋病临床试验单位，首席研究员 Thira Sirisanthana。 CMU CTU 由位于 CMU 健康科学研究所 (RIHES) 的行政部门组成，主要资源包括样本采集、处理和运输、临床实验室评估、数据管理、药学、监管合规、财务管理和行政被安置。步行即可到达 CMU 医学院的临床设施。该 CTU 将拥有 3 个临床研究中心 (CRS)，即 GMU 艾滋病临床试验组临床研究中心 (CMU ACTG C​​RS)，中心负责人 Khuanchai Supparatpinyo，隶属于新成立的艾滋病临床试验组 (ACTG) 网络； HIV 疫苗试验网络临床研究站点 (CMU HVTN CRS)，站点负责人 Vinai Suriyanon，隶属于新成立的 HIV 疫苗试验网络 (HVTN)；以及儿科产科临床研究中心 (CMU PEDOB CRS)，中心负责人 Virat Sirisanthana 将重点关注艾滋病毒母婴传播的研究重点，以及儿童、青少年临床管理和转化研究的优化和孕妇。 RIHES 及其合作者于 1988 年开始在工作室中进行艾滋病毒/艾滋病研究，以监测献血者中的传染病标志物。 1991 年，在洛克菲勒基金会的资助下，RIHES 研究了应征入伍者中艾滋病毒感染的流行病学，后来扩大到包括其他人群，如性工作者、性病诊所患者、注射吸毒者、非注射吸毒者、工厂工人、患有艾滋病的夫妇等。受感染的男性伴侣和社区人群。与约翰·霍普金斯大学、泰国皇家陆军和公共卫生部建立了合作伙伴关系。研究经费支持来自 NIAID、NICHD、NIDA、NIMH、CDC/CONRAD、AIDSCAP/USAID、WRAIR、WHO 和洛克菲勒基金会。泰国是亚洲第一个出现严重艾滋病流行的国家。泰国的疫情曲线领先印度、中国和越南5至10年。 由于亚洲国家有着相似的文化，泰国拥有领导他们进行艾滋病预防和治疗研究的基础设施和经验。最后，泰国可能是世界上唯一可以对 CRF_01 AE 形式的 HIV 进行最佳研究的国家。 行政部分：